Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 18Carcinoma, Hepatocellular 9Neoplasms 8Melanoma 7Squamous Cell Carcinoma of Head and Neck 6Nasopharyngeal Carcinoma 6Triple Negative Breast Neoplasms 5Neoplasm Metastasis 5Esophageal Neoplasms 5Recurrence 4Esophageal Squamous Cell Carcinoma 4Colonic Neoplasms 4Stomach Neoplasms 3Rectal Neoplasms 3Pancreatic Neoplasms 3Lung Neoplasms 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Solid Cancers 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Ovarian Neoplasms 2Gastric / Gastroesophageal Junction Adenocarcinoma 2EBV-associated Tumors 2Cholangiocarcinoma 2Breast Neoplasms 2Bites and Stings 2Biliary Tract Neoplasms 2Advanced Solid Tumors 2

Interventions

pembrolizumab 1Nivolumab 1Immune Checkpoint Inhibitors 1DEAE-Dextran 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Oligoprogressive × Immune Checkpoint Inhibitors × 1 year × Clear all
NCT05846659 2026-05-15

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

ImmuneSensor Therapeutics Inc.

Phase 2 Terminated
16 enrolled 13 charts

Oligoprogressive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡